Business Wire

Wolters Kluwer releases its 2025 Future Ready Accountant report, highlighting key trends in the global tax & accounting industry

8.10.2025 14:00:00 CEST | Business Wire | Press Release

Share

Wolters Kluwer Tax and Accounting is proud to release the second edition of its global report, Future Ready Accountant. The report delivers a data-driven analysis of the global tax and accounting profession. Drawing on insights from over 2,700 professionals worldwide, Future Ready Accountant reveals how firms are evolving to meet rising client expectations, embrace advanced technologies like Artificial Intelligence (AI), and build resilient, insight-driven business models. The report highlights that accelerated AI adoption, advisory-first engagement, and cloud integration are redefining firm purpose, talent strategy, and client service in a rapidly changing global landscape.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008689553/en/

Jason Marx, CEO of Wolters Kluwer Tax & Accounting, commented, “The 2025 Future Ready Accountant report reveals a profession in strategic transformation. Firms are moving beyond tactical fixes to embrace long-term strategies centered on advisory services, talent development, and technology integration. AI is no longer a future consideration—it’s a present-day imperative that firms need to embrace not just to survive but to thrive and grow. As firms embed AI and automation into their workflows, they’re redefining how value is delivered, decisions are made, and client relationships are built. These shifts aren’t just operational—they signal a broader redefinition of firm purpose, long-term strategy, and client engagement models that drive meaningful results.”

The global report features exclusive editions for the U.S., Canada, Europe, and APAC markets - offering region-specific insights and analysis.

“This report is important to the tax and accounting industry, as it not only captures global trends but also provides regional insights—empowering firms to tailor their strategies to specific market needs and navigate the significant shifts reshaping the profession,” said Marx.

Comparative findings from Future Ready Accountant

The 2025 Future Ready Accountant report marks a significant evolution in the global accounting landscape compared to 2024. This year, AI adoption has surged—rising from 9% in 2024 to 41% in 2025—indicating a radical shift from cautious experimentation to confident integration across firm operations. This year’s findings show that 77% of firms plan to increase AI investment, with 35% already using it daily. Firms are embedding AI into workflows to enhance client service and engagement models, automate tasks, and generate strategic insights.

On the power of AI, Marx commented: “AI is redefining how professionals access and apply authoritative knowledge. Built on a responsible framework, AI delivers transparent, source-linked insights while rigorously safeguarding user data. This year’s report shows that AI adoption has more than quadrupled globally, signaling a shift from experimentation to operational reliance. Firms leveraging AI are working faster, with greater precision and confidence, transforming how strategic decisions are made and how client value is delivered.”

Additionally, advisory services have become nearly universal, with 93% of firms offering them—up from 83% in 2024. The emphasis has moved from simply expanding offerings to using AI and data to personalize and scale client advisory. Talent strategies have matured as well; while last year’s focus was on attracting and retaining skilled professionals, this year firms are prioritizing enablement, with 31% citing advanced technical skill development as a top staffing challenge.

Cloud adoption and tech integration continue to drive growth. In 2024, 62% of firms used cloud technology and those with high integration saw 78% revenue growth. In 2025, 52% of firms expanded cloud-based solutions, and 87% of those with highly integrated systems reported revenue growth. The evolution toward digital maturity is now seen as an enabler of innovation, resilience, and long-term success.

Global Key Findings 2025 Future Ready Accountant

Transformation Over Tactics

Firms worldwide are moving beyond tactical responses to embrace strategic transformation. The profession is rapidly evolving due to artificial intelligence, cloud integration, and heightened client expectations for deeper insights. Firms are redefining their purpose, strategy, and client engagement models to drive meaningful results.

Growth and Profitability Surge

  • Revenue Growth: 83% of firms globally reported increased revenue, up from 72% in 2024.
  • Profitability: 79% of firms saw improved profitability, up from 74% last year.
  • This momentum is consistent across regions: Asia Pacific (84%), North America (84%), and Europe (80%). Nearly one in four firms qualify as high-growth (10%+ revenue growth), demonstrating that high performance is not limited by scale.

AI as a Core Capability

  • AI Adoption: AI usage has more than quadrupled in one year, rising from 9% to 41%.
  • Routine Use: 72% of firms now use AI at least weekly, with 35% using it daily.
  • Investment: 77% of firms plan to increase AI investments over the next three years. Among large firms, 40% are targeting double-digit growth in AI spend.
  • Impact: 73% of regular AI users report better-than-expected results, especially in client service, financial insights, and efficiency.

Advisory-First Engagement

  • Advisory Services: 93% of firms now offer advisory services (up from 83% in 2024), with nearly half planning to expand offerings in the next year.
  • Client Demand: 35% of clients are asking firms to provide strategic business advice.
  • Data-Driven: 87% of firms use client data to uncover and tailor advisory opportunities. AI is enhancing advisory delivery, with 41% of high-growth firms reporting better-than-expected results from AI in improving client guidance.

Technology Integration and Cloud Adoption

  • Cloud Solutions: 52% of firms adopted or expanded cloud-based solutions.
  • Workflow Automation: 47% plan to increase workflow automation and enhance digital communication with clients.
  • Integration: 87% of professionals whose technology is highly integrated (at least 75%) experienced revenue growth.

Talent and Future of Work

  • Talent Strategy: Firms are shifting from reactive hiring to strategic enablement, investing in flexibility, automation, and skill-building.
  • Technical Skills: 31% of firms globally cited developing advanced technical skills as a top staffing challenge, up from 27% last year.
  • Staff Demand: Staff expectations for better technology tools surged to 29%, a 10-point increase over last year.

Private Equity and M&A Trends in the last three years

  • Mergers: 26% of firms report having merged with another firm.
  • Private Equity: 32% received private equity investment.
  • Acquisitions: 27% acquired a firm.

Access the Future Ready Accountant Report

Individuals are encouraged to visit https://www.wolterskluwer.com/en/know/future-ready-accountant to access the Future Ready Accountant report and gain insights into the key trends shaping the future of tax and accounting.

# # #

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com and follow us on LinkedIn, Facebook, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008689553/en/

Contacts

Media Contacts
Shannon Wherry
Associate Director, External Communications
Wolters Kluwer Tax & Accounting
Office: +1 972-209-2767
shannon.wherry@wolterskluwer.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye